Brooks Laboratories Past Earnings Performance
Past criteria checks 0/6
Brooks Laboratories's earnings have been declining at an average annual rate of -3.8%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
-3.8%
Earnings growth rate
3.6%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 4.2% |
| Return on equity | -18.1% |
| Net Margin | -19.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Brooks Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 745 | -143 | 109 | 0 |
| 30 Sep 23 | 680 | -154 | 122 | 0 |
| 30 Jun 23 | 618 | -185 | 144 | 0 |
| 31 Mar 23 | 632 | -209 | 177 | 0 |
| 31 Dec 22 | 790 | -202 | 209 | 0 |
| 30 Sep 22 | 827 | -218 | 217 | 0 |
| 30 Jun 22 | 865 | -219 | 207 | 0 |
| 31 Mar 22 | 912 | -113 | 195 | 0 |
| 31 Dec 21 | 778 | -299 | 180 | 0 |
| 30 Sep 21 | 788 | -258 | 166 | 0 |
| 30 Jun 21 | 872 | -176 | 154 | 0 |
| 31 Mar 21 | 772 | -194 | 146 | 0 |
| 31 Dec 20 | 815 | -180 | 145 | 0 |
| 30 Sep 20 | 808 | -183 | 142 | 0 |
| 30 Jun 20 | 653 | -235 | 139 | 0 |
| 31 Mar 20 | 697 | -244 | 140 | 0 |
| 31 Dec 19 | 660 | -154 | 143 | 0 |
| 30 Sep 19 | 612 | -149 | 143 | 0 |
| 30 Jun 19 | 612 | -148 | 126 | 0 |
| 31 Mar 19 | 550 | -148 | 125 | 0 |
| 31 Dec 18 | 544 | -101 | 126 | 0 |
| 30 Sep 18 | 602 | -106 | 127 | 0 |
| 30 Jun 18 | 592 | -116 | 127 | 0 |
| 31 Mar 18 | 557 | -138 | 126 | 0 |
| 31 Dec 17 | 555 | -124 | 114 | 0 |
| 30 Sep 17 | 487 | -93 | 103 | 0 |
| 30 Jun 17 | 493 | -56 | 88 | 0 |
| 31 Mar 17 | 575 | 17 | 88 | 0 |
| 31 Dec 16 | 639 | 75 | 83 | 0 |
| 30 Sep 16 | 707 | 98 | 82 | 0 |
| 30 Jun 16 | 774 | 108 | 77 | 0 |
| 31 Mar 16 | 800 | 106 | 75 | 0 |
| 31 Dec 15 | 828 | 84 | 147 | 0 |
| 30 Sep 15 | 856 | 73 | 141 | 0 |
| 30 Jun 15 | 867 | 94 | 49 | 0 |
| 31 Mar 15 | 852 | 95 | 58 | 0 |
| 31 Dec 14 | 805 | 91 | 139 | 0 |
| 30 Sep 14 | 760 | 88 | 134 | 0 |
| 30 Jun 14 | 796 | 69 | 126 | 0 |
| 31 Mar 14 | 853 | 72 | 139 | 0 |
| 31 Dec 13 | 888 | 49 | 91 | 0 |
| 30 Sep 13 | 929 | 65 | 137 | 0 |
| 30 Jun 13 | 883 | 75 | 144 | 0 |
Quality Earnings: 533543 is currently unprofitable.
Growing Profit Margin: 533543 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 533543 is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare 533543's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 533543 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: 533543 has a negative Return on Equity (-18.05%), as it is currently unprofitable.